Sector: Healthcare | Industry: Healthcare Facilities & Services |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 4399 SANTA ANITA AVE EL MONTE CA 91731 |
Tel: | 1-415-2174964 |
Website: | https://www.fulgentgenetics.com |
IR: | See website |
Key People | ||
Ming Hsieh Chairman of the Board, Chief Executive Officer | Jian Xie President, Chief Operating Officer | Paul Kim Chief Financial Officer | Hanlin Gao Chief Scientific Officer, Laboratory Director |
Business Overview |
Fulgent Genetics, Inc. is a technology-based genetic company with a laboratory services business and a therapeutic development business. The Company's laboratory services business includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile (PK) profile of new and existing cancer drugs. Its technology platform for its laboratory services business includes gene probes, data suppression and comparison algorithms, learning software, and laboratory information management systems. The platform provides a test menu, the ability to rapidly develop and launch new tests and customizable test offerings. The Company also offers next-generation sequencing (NGS) services. |
Financial Overview |
For the fiscal year ended 31 December 2023, Fulgent Genetics Inc revenues decreased 53% to $289.2M. Net loss totaled $167.8M vs. income of $143.4M. Revenues reflect Insurance segment decrease of 60% to $151.9M, Institutional segment decrease of 44% to $134.2M, United States segment decrease of 55% to $269M. Net loss reflects Research and development increase of 44% to $26.6M (expense). |
Employees: | 1,184 as of Feb 15, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $224.20M as of Mar 31, 2024 |
Annual revenue (TTM): | $289.21M as of Mar 31, 2024 |
EBITDA (TTM): | -$49.15M as of Mar 31, 2024 |
Net annual income (TTM): | -$167.83M as of Mar 31, 2024 |
Free cash flow (TTM): | $4.80M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 29,900,666 as of Mar 21, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |